Last Updated:


quotes and stock data delayed 15 minutes


Burn Rate (Qtr)

Company Profile

Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

RYONCIL™ (Remestemcel-L)

Acute graft-versus-host disease (aGVHD) – Pediatric

BLA Approval

December 2020 (Est)

MPC-06-ID (Rexlemestrocel)

Chronic Low Back Pain

Phase 3

Q4 2020

REVASCOR® (Rexlemestrocel)

Advanced Heart Failure

Phase 3

Q4 2020

Remestemcel-L (mesenchymal stem cells)


Phase 3 (Final Interim Analysis)

December 2020 (Est)


Crohn’s Disease

Phase 2


Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon